Use of erythropoetin in haemato-oncology and radiation therapy;Erythropoetin - Einsatz in hamatoonkologie und strahlentherapie

Deutsche Medizinische Wochenschrift

Volumn 125, Issue 19, 2000, Pages 603-607

  Zahner, Johannes ^a  

^a JANSSEN CILAG GMBH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; BLOOD DISEASE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL PROTOCOL; DRUG INDICATION; DRUG UTILIZATION; HUMAN; HYPOXIA; PROGNOSIS; RADIATION INJURY; REVIEW; BLOOD; CELL HYPOXIA; DRUG EFFECT; RADIOTHERAPY; TREATMENT OUTCOME;

ANEMIA; CELL HYPOXIA; ERYTHROPOIETIN; ERYTHROPOIETIN, RECOMBINANT; HEMATOLOGIC NEOPLASMS; HUMANS; PROGNOSIS; RADIOTHERAPY; TREATMENT OUTCOME;

EID: 0034640246     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-1024370     Document Type: Review

References (53)

1. 1 Miller C, Jones R, Piantadosi S, Abeloff MD, Spivak JL. Decresaed erythropoetin response in patients with the anemia of cancer. N Engl J Med 1990; 322: 1689-1692
2. 2 Ludwig H, Fritz E, Kotzmann H, Höcker P, Gisslinger H, Barnas U. Erythropoietin treatment of anemia associated with multiple myeloma. New Engl J Med 1990; 322: 1693-1699
3. 3 Henry D, Abels R. Recombinant human erythropoietin in the treatment of cancer and chemotherapy-induced anemia: results of double-blind and open-label follow-up studies. Sem Oncol 1994; 21: 21-28
4. 4 Cascinu S, Fedeli A, Del Ferro E, Fedeli SL. Recombinant human erythropoietin treatment in cisplatin-associated anemia: a randomized, double-blind trial with placebo. J Clin Oncol 1994; 12: 1058-1062
5. 5 Del Mastro L, Venturini M, Lionetto R, Garrone O, Melioli G, Pasquetti W, Sertoli MR, Bertelli G, Canavese G, Costantini M, Rosso R. Randomized Phase III trial evaluating the role of erythropoetin in the prevention of chemotherapy-induced anemia. J Clin Oncol 1997; 15: 2715-2721
6. 6 Demetri G, Kris M, Wade J, Degos L, Cella D. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. J Clin Oncol 1998; 16: 3412-3425
7. 7 Glaspy J, Bukowski R, Steinberg D, Taylor C, Tchekmedyian S, Vadhan-Raj S. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology paractice. J Clin Oncol 1997; 15: 1218-1234
8. 8 Yellen SB, Cella DF, Webster K, Blendowski C, Kaplan E. Measuring fatigue and other anemia-related symptoms with the functional assessment of cancer therapy (FACT) measurement system. J Pain Symptom Manage 1997; 13: 63-74
9. 9 Cleeland CS, Demetri GD, Glaspy J, Cella DF, Portenoy RK, Cremieux PY, Itri LM. Identifying hemoglobin level for optimal quality of life: results of an incremental analysis. Proc ASCO 1999; 18: 2215
10. 10 Sweeney P, Nicolae D, Ignacio L, Chen L, Roach M, Wara W, Marcus KC, Vijayakumar S. Effect of subcutaneous recombinant human erythropoetin in cancer patients receiving radiotherapy: final report of a randomized, open-labelled, phase II trial. British J Cancer 1998; 77: 1996-2002
11. 11 Ludwig H, Fritz E, Leitgeb C, Pecherstorfer M, Samonigg H, Schuster J. Prediction of response to erythropoietin treatment in chronic anemia of cancer. Blood 1994; 84: 1056-1063
12. 12 Urabe A, Mitani K, Yoshinaga K, Iki S, Yagisawa M, Ohbayashi Y, Takaku F. Serum Erythropoietin titers in hematological malignancies and related diseases. Int J Cell Cloning 1992; 1: 333-337
13. 13 Littlewood T, Bajetta E, Cella D. Efficacy and quality of life outcomes of epoetin alfa in a double-blind placebo-controlled multicenter study of cancer patients receiving non-platinum containing chemotherapy. Proc ASCO 1999; 18: 2217
14. 14 Gabrilove JL, Einhorn LH, Livingston RB, Winer E, Cleeland CS. Once-weekly dosing of epoetin alfa is similar to three-weekly dosing in increasing hemoglobin and quality of life. Proc ASCO 1999; 18: 2216
15. 15 Hellström-Lindberg E. Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies. Br J Haematol 1995; 89: 67-71
16. 16 Rose E, Abels R, Nelson R, McCollough DM, Lessin L. The use of r-Hu-Epo in the treatment of anaemia related myelodysplasia (MDS). Br J Haematol 1995; 89: 831-837
17. 17 Hellström-Lindberg E, Negrin R, Stein R, Krantz S, Lindberg G, Vardiman J, Öst A, Greenberg P. Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model. Br J Haematol 1997; 99: 344-351
18. 18 Schwarz G. Über Desensibilisierung gegen Röntgen- und Radiumstrahlen. Münch med Wschr 1909; 24: 1-2
19. 19 Hokhusen H. Beiträge zur Biologie der Strahlenwirkung. Untersuchungen an Askarideneiern. Pflügers Arch Ges Physiol 1921; 187: 1-24
20. 20 Molls M, Stadler P, Becker A. Relevance of oxygen in radiation oncology. Strahlenther Onkol 1998; 174 (Suppl IV): 13-16
21. 21 Graeber T, Osmanian C, Jacks T, Housman D, Koch C, Lowe S, Giaccia J. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumors. Nature 1996; 379: 88-91
22. 22 Reynolds T, Rockwell S, Glazer P. Genetic instability induced by the tumor microenvironment. Cancer Res 1996; 56: 5754-5757
23. 23 Albain KS, Crowley JJ, LeBlanc M, Livingstone RB. Survival determants in extensive-stage non-small lung cancer. J Clin Oncol 1991; 9: 1618-1626
24. 24 Ohlhauser C, Bülzebruck H, Ebert W, Drings P, Wannenmacher M. Prognostic factors for survival in inoperable non-small-cell lung cancer: A multivariate regression analysis of 456 patients with radiation therapy. Oncology 1997; 2: 126-131
25. 25 Takigawa N, Segawa Y, Okahara M, Maeda Y, Takata I, Kataoka M, Fujii M. Prognostic factors for patients with advanced non-small cell lung cancer: univariate and multivariate analyses inducing recursive partitioning and amalgamation. Lung Cancer 1996; 15: 67-77
26. 26 Obermair A, Handisurya A, Kaider A, Sevelda P, Kölbl H, Gitsch G. The relationship of pretreatment serum hemoglobin level to the survival of epithelian ovarian carcinoma patients. A prospective review Cancer 1998; 83: 726-731
27. 27 Tarnawski R, Skladowski K, Maciejewski B. Prognostic value of hemoglobin concentration in radiotherapy for cancer of supraglottic larynx. Int J Radiat Oncol Biol Phys 1997; 38: 1007-1011.
28. 28 van Acht MJ, Hermans J, Boks DE, Leer JW. The prognostic value of hemoglobin and a decrease in hemoglobin during radiotherapy in laryngeal carcinoma. Radiotherapy and Oncology 1992; 23: 229-235
29. 29 Fein DA, Lee WR, Hanlon AL, Ridge JA, Langer CJ, Curran WJ, Coia LR. Pretreatment Hemoglobin level influences local control and survival of T1-T2 squamous cell carcinomas of the glottic larynx. J Clin Oncol 1995; 13: 2077-2083
30. 30 Pedersen D, Søgaard H, Overgaard J, Bentzen SM. Prognostic value of pretreatment factors in patients with locally advanced carcinoma of the uterine cervix treated by radiotherapy alone. Acta Oncologica 1995; 34: 787-795
31. 31 Rader JS, Haraf DJ, Halpern HJ, Rotmensch J, Spelbring DR, Sutton H, Javaheri G, Weichselbaum RR. Radiation therapy in the treatment of cervical cancer: the university of Chicago/Michael Reese hospital experience. J Surg Oncol 1990; 44 (3): 157-165
32. 2 tension measurements. Cancer Res 1991; 51: 3316-3322
33. 33 Fleckenstein W, Jungblut JR, Suckfüll M, Hoppe W, Weiss C. Sauerstoffdruckverteilungen in Zentrum und Peripherie maligner Kopf-Hals-Tumoren. Dtsch Z Mund Kiefer Gesichts Chir 1993; 12: 205-211
34. 34 Kallinowski F, Buhr H. Tissue oxygenation of primary, metastatic and xenografted rectal cancers. In: Vaupel P, Kelleher D, Gründeroth M (ed): Tumoroxygenation. Stuttgart, Fischer, 1995: 205-209
35. 2 histography. Br J Cancer 1992; 66: 919-924
36. 36 Fyles AW, Milosevic M, Wong R, Kavanagh MC, Pintilie M, Sun A, Chapman W, Levin W, Manchul L, Keane TJ, Hill RP. Oxygenation predicts radiation response and survival in patients with cervix cancer. Radiotherapy an Oncology 1988; 48: 149-156
37. 37 Brizel DM, Rosner GL, Prosnitz LR, Dewhirst MW. Patterns and variability of tumor oxygenation in human soft tissue sarcomas, cervix carcinomas and lymph node metastases. Int J Radiat Oncol Biol Phys 1995; 32: 1121-1125
38. 38 Höckel M, Schlenger K, Mitze M, Schäffer U, Vaupel P. Hypoxia and radiation response in human tumors. Sem Radiat Oncol 1996; 6: 3-9
39. 39 Gatenby RA, Kessler HB, Rosenbaum JS, Coia LR, Moldofsky PJ, Hartz WH, Broder GJ. Oxygen distribution in sqamous cell carcinoma metastasis and its relationship to outcome of radiation therapy. Int J Radiat Oncol Biol Phys 1988; 14: 831-838
40. 40 Nordsmark M, Overgaard M, Overgaard J. Pretreatment oxygenation predicts radiation response in advanced sqamous cell carcinoma of the hed and neck. Radiotherapy and Oncology 1996; 41: 31-39
41. 41 Brizel DM, Sibley GS, Prosnitz LR, Scher RL, Dewhirst MW. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 1997; 38: 285-289
42. 42 Brizel DM, Scully SP, Harrelson JM, Layfield LJ, Bean JM, Prosnitz LR, Dewhirst MW. Tumor oxygenation predicts for the likelehood of distant metastasis in human soft tissue sarcoma. Cancer Res 1996; 56: 941-943
43. 2 in cervix carcinoma. Gynecol Oncol 1997; 64: 230-236
44. 44 Girinski T, Pejovic-Lenfant MH, Bourhis J, Campana F, Cosset JM, Petit C, Malaise EP, Haie C, Gerbaulet A, Chassagne D. Prognostic value of hemoglobin concentrations and blood transfusions in advanced carcinoma of the cervix treated by radiation therapy: results of a retrospective study of 386 patients. Int J Radiat Oncol Biol Phys 1989; 16: 37-42
45. 45 Vijayakumar S, Roach M, Wara W, Chan SK, Ewing C, Rubin S, Sutton H, Halpern H, Awan A, Houghton A. Effect of subcutaneous recombinant human erythropoetin in cancer patients receiving radiotherapy: preliminary results of a randomized, open-labeled, phase II trial. Int J Radiation Oncology Biol Phys 1993; 26: 721-729
46. 46 Dusenbery KE, McGuire WA, Holt PJ, Carson LF, Fowler JM, Twiggs LB, Potish RA. Erythropoetin increases hemoglobin during radiation therapy for cervical cancer. Int J Radiation Oncology Biol Phys 1994; 29: 1079-1084
47. 47 Lavey R, Dempsey W. Erythropoetin increases hemoglobin in cancer patients during radiation. Int J Radiation Oncology Biol Phys 1993; 27: 1147-1152
48. 48 Beinert T, Mergenthaler H-G, Sezer O, Löffel J, Binder D, Oehm C, Werner T, Possinger K. Hypoxie bei soliden Tumoren. Dtsch med Wschr 1999; 12: 534-540
49. 49 Thews O, Koenig R, Kelleher DK, Kutzner J, Vaupel P. Enhanced radiosensitivity in experimental tumours following erythropoietin treatment of chemotherapy-induced anaemia. Br J Cancer 1998; 78: 752-756
50. 50 Glaser C, Millesi W, Gössweiner S, Leitha T, Dobrowsky W, Kornek GV. r-HuErythropoetin supply incresases efficacy of neoadjuvant radio-chemotherapy in patients with oral squamous cell carcinoma. Proc ASCO 1998; 17: 397a
51. 51 Antonadou D, Cardamakis E, Sarris G et al. Effect of the administration of recombinant human erythropoetin in patients with pelvic malignancies during radiotherapy. Radiother Oncol 1998; 48 Suppl: S122
52. 52 Glaser C, Millesi W, Wanschitz B, Schüll B, Lang S, Leitha T, Kornek GV. R-huErythropoetin treatment increases efficacy of neoadjuvant radiochemotherapy and improves cancer free survival of patient with oral squamousa cell carcinoma: a 17 months follow up. Proc ASCO 1999; 18: 1543
53. 53 Silver D, Piver S. Effects of recombinant human erythropoetin on the antitumor effect of cisplatin in scid mice bearing human ovarian cancer: a possible oxygen effect. Gynecol Oncol 1999; 73: 280-284